Literature DB >> 17001081

Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A.

Núria Canela1, Mar Orzáez, Raquel Fucho, Francesca Mateo, Ricardo Gutierrez, Antonio Pineda-Lucena, Oriol Bachs, Enrique Pérez-Payá.   

Abstract

The protein-protein complexes formed between different cyclins and cyclin-dependent kinases (CDKs) are central to cell cycle regulation. These complexes represent interesting points of chemical intervention for the development of antineoplastic molecules. Here we describe the identification of an all d-amino acid hexapeptide, termed NBI1, that inhibits the kinase activity of the cyclin-dependent kinase 2 (cdk2)-cyclin A complex through selective binding to cyclin A. The mechanism of inhibition is non-competitive for ATP and non-competitive for protein substrates. In contrast to the existing CDKs peptide inhibitors, the hexapeptide NBI1 interferes with the formation of the cdk2-cyclin A complex. Furthermore, a cell-permeable derivative of NBI1 induces apoptosis and inhibits proliferation of tumor cell lines. Thus, the NBI1-binding site on cyclin A may represent a new target site for the selective inhibition of activity cdk2-cyclin A complex.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001081     DOI: 10.1074/jbc.M603511200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.

Authors:  Archana Balakrishnan; Arpita Vyas; Kaivalya Deshpande; Dinesh Vyas
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 2.  Cell cycle kinases as therapeutic targets for cancer.

Authors:  Silvia Lapenna; Antonio Giordano
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

Review 3.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

4.  Role of CDK5/cyclin complexes in ischemia-induced death and survival of renal tubular cells.

Authors:  Tatiana Guevara; Mónica Sancho; Enrique Pérez-Payá; Mar Orzáez
Journal:  Cell Cycle       Date:  2014-03-25       Impact factor: 4.534

5.  Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) signaling pathway with a regulator of calcineurin-derived peptide without affecting general calcineurin phosphatase activity.

Authors:  Ma Carme Mulero; Anna Aubareda; Mar Orzáez; Joaquim Messeguer; Eva Serrano-Candelas; Sergio Martínez-Hoyer; Angel Messeguer; Enrique Pérez-Payá; Mercè Pérez-Riba
Journal:  J Biol Chem       Date:  2009-02-03       Impact factor: 5.157

6.  Histone deacetylase 3 regulates cyclin A stability.

Authors:  Miriam Vidal-Laliena; Edurne Gallastegui; Francesca Mateo; Marian Martínez-Balbás; Maria Jesús Pujol; Oriol Bachs
Journal:  J Biol Chem       Date:  2013-06-11       Impact factor: 5.157

7.  The transcriptional co-activator PCAF regulates cdk2 activity.

Authors:  Francesca Mateo; Miriam Vidal-Laliena; Núria Canela; Annalisa Zecchin; Marian Martínez-Balbás; Neus Agell; Mauro Giacca; María Jesús Pujol; Oriol Bachs
Journal:  Nucleic Acids Res       Date:  2009-11       Impact factor: 16.971

8.  Degradation of cyclin A is regulated by acetylation.

Authors:  F Mateo; M Vidal-Laliena; N Canela; L Busino; M A Martinez-Balbas; M Pagano; N Agell; O Bachs
Journal:  Oncogene       Date:  2009-06-01       Impact factor: 9.867

9.  Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment.

Authors:  M Orzáez; T Guevara; M Sancho; E Pérez-Payá
Journal:  Cell Death Dis       Date:  2012-10-25       Impact factor: 8.469

10.  Depletion of human histone H1 variants uncovers specific roles in gene expression and cell growth.

Authors:  Mónica Sancho; Erika Diani; Miguel Beato; Albert Jordan
Journal:  PLoS Genet       Date:  2008-10-17       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.